The mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Takeda, ...
PTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several ...
Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February. Taiho Pharmaceutical and Cullinan Therapeutics’ ...
The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts. In a royalty ...
Last month, biopharmas cutting or planning to cut their workforces included Amgen, GSK and Novartis, with Novartis’ layoffs affecting the most people. July brought a sharp year-over-year decrease in ...
Avalyn Pharma and Generate Biomedicines executives discuss the long hours, hard work and rewarding moments of taking their companies public. For Lyn Baranowski, it all comes down to a watch. Asked to ...
Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day for ...
Beyond the legal action, Eli Lilly is calling on healthcare providers, regulatory authorities, online platforms and even logistics companies to help stem the illegal sale of its next-generation asset ...
Looking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles. If you’re interested in working at a pharma or biotech in North ...
BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra. In the transthyretin amyloidosis space, ...
ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns. The FDA has rejected ITM Isotope Technologies’ investigational ...
After a drama-filled year that included two FDA rejections, Replimune has finally secured market approval for its oncolytic immunotherapy RP1 to treat advanced melanoma. The greenlight came after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results